This week's highlights
ETFS S&P Biotech ETF (CURE) was last week’s top performing ETF, returning 6.5%. Domestic resource funds also fared well, with MVR, OZR and QRE all posting strong gains. Australian property funds SLF and VAP were also amongst the top performers. China and emerging markets funds (CNEW and EMKT) declined for the week.
Palladium surged to new all-time highs, with ETFS Physical Palladium (ETPMPD) returning 4.1%. Other precious metals pulled-back last week. Crude oil declined, with OOO falling 4.5% and global energy company fund FUEL down 1.9%.
Total flows into domestically domiciled ETFs were $171m, while outflows totalled $51m. IOZ and GOLD saw the largest inflows for the week, followed by HBRD and MVW. Cash fund AAA saw the bulk of the outflows for the week.
AAA was the most traded fund last week, followed by VAS and STW. VSO, VHY and GOLD saw above average volumes.
ETFS S&P Biotech ETF (CURE) has gained more than 22% over the past two months. A raft of FDA approvals and some high profile acquisitions by large pharmaceutical companies have spurred a recovery across the biotechnology sector following a lacklustre year thus far. Further FDA activity is expected over the coming months.